Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 1
2016 1
2018 1
2020 1
2021 2
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
TAC-TIC use of tacrolimus-based regimens in lupus nephritis.
Kraaij T, Bredewold OW, Trompet S, Huizinga TW, Rabelink TJ, de Craen AJ, Teng YK. Kraaij T, et al. Among authors: bredewold ow. Lupus Sci Med. 2016 Dec 29;3(1):e000169. doi: 10.1136/lupus-2016-000169. eCollection 2016. Lupus Sci Med. 2016. PMID: 28123768 Free PMC article. Review.
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
van Leeuwen JR, Bredewold OW, van Dam LS, Werkman SL, Jonker JT, Geelhoed M, Langeveld APM, Remmelts HHF, van den Broecke MM, Ray A, Rabelink TJ, Teng YKO. van Leeuwen JR, et al. Among authors: bredewold ow. Kidney Int Rep. 2021 Dec 8;7(3):624-628. doi: 10.1016/j.ekir.2021.11.036. eCollection 2022 Mar. Kidney Int Rep. 2021. PMID: 35257076 Free PMC article. No abstract available.
ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial.
Dirikgil E, van Leeuwen JR, Bredewold OW, Ray A, Jonker JT, Soonawala D, Remmelts HHF, van Dam B, Bos WJ, van Kooten C, Rotmans J, Rabelink T, Teng YKO. Dirikgil E, et al. Among authors: bredewold ow. BMJ Open. 2022 Sep 21;12(9):e061339. doi: 10.1136/bmjopen-2022-061339. BMJ Open. 2022. PMID: 36130755 Free PMC article.
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Kraaij T, et al. Among authors: bredewold ow. J Autoimmun. 2018 Jul;91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7. J Autoimmun. 2018. PMID: 29636274 Clinical Trial.
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Kraaij T, et al. Among authors: bredewold ow. Nephrol Dial Transplant. 2021 Jul 23;36(8):1474-1483. doi: 10.1093/ndt/gfaa117. Nephrol Dial Transplant. 2021. PMID: 32591783 Free PMC article.
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial.
Bredewold OW, Chan J, Svensson M, Bruchfeld A, de Fijter JW, Furuland H, Grinyo JM, Hartmann A, Holdaas H, Hellberg O, Jardine A, Mjörnstedt L, Skov K, Smerud KT, Soveri I, Sørensen SS, Zonneveld AV, Fellström B. Bredewold OW, et al. Kidney Med. 2022 Nov 18;5(1):100574. doi: 10.1016/j.xkme.2022.100574. eCollection 2023 Jan. Kidney Med. 2022. PMID: 36593877 Free PMC article.
Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
van Dam LS, Oskam JM, Kamerling SWA, Arends EJ, Bredewold OW, Berkowska MA, van Dongen JJM, Rabelink TJ, van Kooten C, Teng YKO. van Dam LS, et al. Among authors: bredewold ow. Front Immunol. 2020 Dec 15;11:566732. doi: 10.3389/fimmu.2020.566732. eCollection 2020. Front Immunol. 2020. PMID: 33384685 Free PMC article.
Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts.
Bredewold OW, van Oeveren-Rietdijk AM, Florijn B, Rotmans JI, de Fijter JW, van Kooten C, van Zonneveld AJ, de Boer HC. Bredewold OW, et al. Transpl Immunol. 2024 Feb;82:101976. doi: 10.1016/j.trim.2023.101976. Epub 2024 Jan 8. Transpl Immunol. 2024. PMID: 38199271 Free article. Clinical Trial.